Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

SanBio (4592 JP): Akuugo Awaiting NHI Price Listing and Launch, SB623 Trial Progressing Well In US

SanBio Co Ltd (4592 JP): International Offering Attractive, Akuugo Approval Is Next Big Trigger

SanBio Co Ltd (4592 JP): Akuugo Shipments Expected To Commence In 2QFY26, New Credit Line In Place

SanBio Co Ltd (4592 JP): Akuugo Approval Awaited; Plans Negotiation for Ischemic Stroke Trials

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sanbio-co-ltd" target="_blank" data-smartkarma-citation="entities:24540:1" rel="noopener">SanBio Co Ltd (4592 JP)</a> reported higher operating loss (~¥2.7B) in 9MFY26 as R&amp;D expenses rose for partial changes approval of Akuugo. Net loss widened too.</li>
<li>MHLW approved the partial change to the marketing approval and revised the associated approval conditions. Going forward, after the NHI price listing, the company plans to launch Akuugo.</li>
<li>The approval and international offering augur well. SanBio remains a risky bet with probability of a high return going up with every milestone, the launch of Akuugo being the next.</li>
</ul>



SanBio Co Ltd (4592 JP) reported higher operating loss (~¥2.7B) in 9MFY26 as R&amp;D expenses rose for partial changes approval of Akuugo. Net loss widened too.
MHLW approved the partial change to the marketing approval and revised the associated approval conditions. Going forward, after the NHI price listing, the company plans to launch Akuugo.
The approval and international offering augur well. SanBio remains a risky bet with probability of a high return going up with every milestone, the launch of Akuugo being the next.


SanBio Co (4592 JP): Akuugo Launch Awaited, Groundwork Being Laid for New Indications & Geographies